New! Dexlansoprazole 60 mg Delayed-Release Capsules

New! Dexlansoprazole 60 mg Delayed-Release Capsules Wexford Laboratories is proud to present its latest pharmaceutical innovation: Dexlansoprazole 60 mg delayed-release capsules, a proton pump inhibitor (PPI) widely recommended for the treatment of erosive esophagitis, as well as gastric and duodenal ulcers. Patient Benefits Our Dexlansoprazole offers multiple advantages for patients requiring effective treatment for gastroesophageal … Read more

Most In-Demand Medications in Bolivia – 2024

At Wexford Laboratories, we understand market trends and work to meet the needs of our clients. Today, we want to share a glimpse of the most in-demand medications in 2024 and demonstrate how we can be your trusted partner in manufacturing these essential products. The Bolivian Institute of Foreign Trade (IBCE) reports statistics related to … Read more

A Unique Experience! Expo Pharma Milan 2024: Innovation and Connections for Our Clients

At Wexford, we don’t just focus on manufacturing formulations; we also strive to stay informed and up-to-date on everything happening in the global pharmaceutical field. Yes, at Wexford, we do the fieldwork for you! This year, we sent a team from Wexford Laboratories to one of the most prominent pharmaceutical expos in the world. The … Read more

Wexford Laboratories launches a new product, Ondansetron 4 mg/2 mL Injectable Solution, driven by high demand projections according to studies.

Wexford Laboratories now has available one of the most commonly used antiemetics for the treatment of Nausea and Vomiting: Ondansetron 4 mg/2 mL Injectable Solution, a product highly utilized by Oncologists and Surgeons. If you want to discover how our New Formulation can revitalize your product portfolio and help you stay at the forefront of … Read more

Dexketoprofen 50mg/2ml Injectable Solution: A New Option for Pain Relief

Wexford Laboratories Adds Dexketoprofen 50mg/2ml Injectable Solution to Its Product List, Offering Rapid and Effective Relief for Acute Pain March 2024: In a continuous effort to improve the quality of life for patients suffering from acute pain, Wexford Laboratories is proud to announce the launch of its new product: Dexketoprofen 50mg/2ml Injectable Solution. This innovative … Read more

Wexford announces approval of In Vitro Bioequivalence

Metformin is a widely prescribed medication used for the management of type 2 diabetes, a chronic disease that affects millions of people worldwide. It is an essential tool for controlling blood sugar levels and improving the overall health and well-being of individuals with diabetes. In vitro bioequivalence testing of Metformin is a crucial step in … Read more

Open chat
[caldera_form id="CF64ee16c372d21"]